Identification of novel determinants of resistance to lapatinib in ERBB2-amplified cancers.
about
TRAPP Complexes in Secretion and AutophagyIn sickness and in health: the role of TRAPP and associated proteins in diseaseSrc mutation induces acquired lapatinib resistance in ERBB2-amplified human gastroesophageal adenocarcinoma modelsSynergistic effects of various Her inhibitors in combination with IGF-1R, C-MET and Src targeting agents in breast cancer cell linesA class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expressionElevated NIBP/TRAPPC9 mediates tumorigenesis of cancer cells through NFκB signalingA bead-based western for high-throughput cellular signal transduction analyses.IGFBP2 modulates the chemoresistant phenotype in esophageal adenocarcinoma.Immunohistochemical prediction of lapatinib efficacy in advanced HER2-positive breast cancer patients.A new role of the Rac-GAP β2-chimaerin in cell adhesion reveals opposite functions in breast cancer initiation and tumor progression.Systematic analysis of tumour cell-extracellular matrix adhesion identifies independent prognostic factors in breast cancer.RAC1: an emerging therapeutic option for targeting cancer angiogenesis and metastasis.Adaptive stress signaling in targeted cancer therapy resistance.Identification of novel therapeutic target genes in acquired lapatinib-resistant breast cancer by integrative meta-analysis.Lapatinib resistance in HER2+ cancers: latest findings and new concepts on molecular mechanisms.Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling.Ferroptosis is induced following siramesine and lapatinib treatment of breast cancer cells.RAC1 GTPase promotes the survival of breast cancer cells in response to hyper-fractionated radiation treatment.
P2860
Q26749341-6B340062-4B39-45B5-A462-D04F3419F960Q27026407-814A21AF-4332-4DDD-BA9C-C4D8C50C885AQ28544422-02840C54-CAAF-4CDA-BE22-88258A6B6172Q33822560-8A036186-C412-44B2-8293-6080E5D614ECQ33991817-63A0338A-756B-45A8-83FF-8296B6493A6BQ35742493-D10C991E-C649-493F-BEC9-C885ED499009Q36141854-35CDE2DF-A8E6-40F7-A02D-E23361F7FFE8Q36413323-1B0FE60A-201E-4BD4-9A35-975192473595Q36729467-BA472C72-E9E1-4693-BEB5-F3C5D6ADA28FQ37317542-D2619C66-1EC5-4655-8C49-480E8EDAD1F8Q37665209-DE499C7E-1BCD-4C47-BAFA-4A8E78EE8DFAQ38145091-CDDB3937-913B-4D9E-9C9B-413441F7C493Q38363739-4992D79F-8BC3-43F1-9C86-E523FCE0BBBEQ38457923-769FE532-661E-411C-AE18-6F9F0FB7BF8CQ38812867-AC0E9D3E-2E96-4CBF-97FE-EC4CDEF8F3CDQ38824661-2C86276E-BA3F-4917-A422-76976BD33656Q41850545-E0322ABF-2A46-4DFB-BE6D-8556B6F51CEAQ42079499-5D61332A-81E7-4E7C-AC8C-96DBC20BCB09
P2860
Identification of novel determinants of resistance to lapatinib in ERBB2-amplified cancers.
description
2013 nî lūn-bûn
@nan
2013 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մարտին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Identification of novel determ ...... ib in ERBB2-amplified cancers.
@ast
Identification of novel determ ...... ib in ERBB2-amplified cancers.
@en
Identification of novel determ ...... ib in ERBB2-amplified cancers.
@nl
type
label
Identification of novel determ ...... ib in ERBB2-amplified cancers.
@ast
Identification of novel determ ...... ib in ERBB2-amplified cancers.
@en
Identification of novel determ ...... ib in ERBB2-amplified cancers.
@nl
prefLabel
Identification of novel determ ...... ib in ERBB2-amplified cancers.
@ast
Identification of novel determ ...... ib in ERBB2-amplified cancers.
@en
Identification of novel determ ...... ib in ERBB2-amplified cancers.
@nl
P2093
P2860
P50
P356
P1433
P1476
Identification of novel determ ...... ib in ERBB2-amplified cancers.
@en
P2093
D Wetterskog
J S Reis-Filho
P2860
P2888
P304
P356
10.1038/ONC.2013.41
P407
P577
2013-03-11T00:00:00Z
P6179
1052013034